Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Novartis AG's top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth.
from Reuters: Health News https://reut.rs/2Hy79of
http://bit.ly/2zwRqiM